KFDA to suspend production of Galamin, etc.

Published: 2002-10-25 06:57:00

Updated: 2002-10-25 06:57:00

The KFDA said it discovered some defects in Kuhnpoong Pharm's manufacturing facilities for injectables with the mixing problems of foreign materials as a results of its special inspection and called for the competent authorities to seal their nine items including Galamin inj. and Mecamol inj.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK